The UK has become the first country to approve the use of an oral medication that can be taken at home to treat Covid-19.
Molnupiravir was given the green light today by the UK’s regulatory body for medicines. The pill “will be a game-changer for the most vulnerable and the immunosuppressed”, said Health Secretary Sajid Javid.
Who will get it?
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The oral antiviral, developed by two US companies – Ridgeback Biotherapeutics and Merck, Sharp & Dohme – has been approved for use by patients with mild to moderate cases of Covid who also present at least one risk factor. Elderly people, diabetics and people with heart disease will be among the first to be offered the treatment.
How does it work?
Molnupiravir works by targeting the enzyme that is responsible for causing the coronavirus to replicate within the body by “introducing errors into its genetic code”, said the BBC. “That should prevent it from multiplying, so keeping virus levels low in the body and reducing the severity of the disease.” Patients can self-administer the medication twice a day, and it is best taken within the first five days of symptoms presenting.
How effective is it?
Clinical trial data showed that the pill “cut the risk of hospitalisation or death by about half” for people at increased risk of developing severe cases of Covid, said the BBC. The Medicines and Healthcare products Regulatory Agency (MHRA) has deemed the treatment both “safe and effective”, with chief executive June Raine describing the medicine as “another therapeutic to add to our armoury against Covid-19”, Sky News reported.
How much does it cost?
The UK has already ordered 480,000 courses of molnupiravir to arrive by the end of the year. Reuters reported that an order for roughly half that amount has also been placed for a similar drug being developed by Pfizer.
The government “has not disclosed” how much the initial Merck, Sharp and Dohme contract has cost, but US authorities struck a deal that worked out at around $700 (£513) per patient, the BBC said. Australia, Singapore and South Korea have also placed orders for the drug.
How long will it take to roll out?
The health secretary said the government is “working at pace” with the NHS to lay out plans to “deploy” the drug to patients “as soon as possible”. He added that it is still “vital” everyone receives a “life-saving Covid-19 vaccine”, as molnupiravir is not a substitute for vaccination.
Penny Ward, a professor in pharmaceutical medicine at King's College London, told the BBC that if trial results are replicated in the UK, “the number of cases requiring hospital admission could be halved and the number of deaths greatly reduced”.
-
Five key questions about the Gaza peace dealThe Explainer Many ‘unresolved hurdles’ remain before Donald Trump’s 20-point plan can get the go-ahead
-
See the Northern Lights from these bucket list destinationsThe Week Recommends The dazzling displays can be spotted across Iceland, Sweden and parts of Canada
-
Crossword: October 7, 2025The Week's daily crossword
-
The new Stratus Covid strain – and why it’s on the riseThe Explainer ‘No evidence’ new variant is more dangerous or that vaccines won’t work against it, say UK health experts
-
Why are autism rates increasing?The Explainer Medical experts condemn Trump administration’s claim that paracetamol during pregnancy is linked to rising rates of neurodevelopmental disorder in US and UK
-
RFK Jr. vaccine panel advises restricting MMRV shotSpeed Read The committee voted to restrict access to a childhood vaccine against chickenpox
-
Texas declares end to measles outbreakSpeed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agencySpeed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Cytomegalovirus can cause permanent birth defectsThe Explainer The virus can show no symptoms in adults
-
RFK Jr. scraps Covid shots for pregnant women, kidsSpeed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sickspeed read The FDA set stricter approval standards for booster shots
